US Drug Pricing Reforms: Navigating the New Landscape with Durable Pharma Plays

The Biden administration’s aggressive push for drug price reforms—including the Most-Favored-Nation (MFN) pricing framework and Medicare negotiation mandates—is reshaping the pharmaceutical sector. While headlines focus on the sector’s immediate risks, the reforms also create opportunities for investors to identify sector leaders with durable pipelines and underfollowed names insulated from price controls through global diversification or innovation.

Sector Stratification: Winners and Losers in the Price Control Era

The reforms will stratify pharmaceutical equities based on three key factors:
1. Exposure to Medicare/Medicaid: Companies reliant on government programs for blockbuster drugs face direct pricing pressure.
2. Portfolio Resilience: Firms with diverse revenue streams (e.g., rare diseases, generics, or non-Medicare therapies) or therapies with no global pricing equivalents will thrive.
3. R&D Focus: Companies prioritizing high-unmet-need areas—such as gene therapies, oncology, or metabolic disorders—will maintain pricing power.

The losers: Legacy companies with narrow portfolios tied to chronic therapies (e.g., statins, insulin) face margin compression.

The winners: Firms with geographically diversified revenue and innovative pipelines will outperform.

Underfollowed Plays: Durable Pipelines and Global Reach

While giants like Eli Lilly and Novo Nordisk dominate headlines, underfollowed names offer asymmetric upside:

1. ANI Pharmaceuticals (ANIP)

• Why buy: ANI’s focus on high-barrier-to-entry generics and rare disease treatments shields it from MFN pricing risks. Its Purified Cortrophin Gel for multiple sclerosis targets a niche market with limited competition.
• Pipeline: 20+ FDA applications pending, including complex formulations. Vertical integration ensures supply chain control and margins.
• Growth: EPS grew 6.8% YoY in 2024, with 2025 estimates hitting $5.47.

2. Biote (BTMD)

• Why buy: Biote’s hormone optimization platform leverages FDA-approved therapies and a network of trained practitioners. Its asset-light model scales efficiently as demand for personalized care grows.
• Pipeline: Expanding into 50+ markets with partnerships in Japan and Europe.
• Growth: EPS is projected to surge 225% to $0.57 in 2025.

3. AbbVie (ABBV) – Strategic Partnerships Pay Off

• Why buy: AbbVie’s $2B+ deals with Gilgamesh Pharmaceuticals (neuroplastogens for psychiatric disorders) and FutureGen Biopharmaceutical (TL1A antibody for IBD) diversify its pipeline beyond Humira.
• Pipeline: FG-M701 (IBD) and UB-VV111 (CAR-T for blood cancers) are 2025 catalysts.

4. Takeda (TAK) – Global Oncology Leader

• Why buy: Takeda’s $2.2B deal with AC Immune for Alzheimer’s immunotherapy ACI-24.060 and its partnership with Ascentage Pharma (olverembatinib for leukemia) position it to dominate Asia-Pacific markets.
• Pipeline: 12 launches planned in 2025, including next-gen COPD therapies.

Geographically Diversified Revenue: A Hedge Against US Price Controls

The reforms target Medicare/Medicaid, making global revenue streams a critical defensive asset.

Sanofi (SNY) – AI-Driven Global Growth

• Why buy: Sanofi’s mRNA partnerships (e.g., with Translate Bio) and AI collaborations (OpenAI for clinical trial optimization) reduce reliance on U.S. pricing.
• Diversification: 60% of 2024 revenue came from Europe/Asia.

Amgen (AMGN) – International Dominance

• Why buy: Amgen’s 2025 sales in Japan (IMDELLTRA®) and Europe (Prolia®) offset U.S. Medicare pressures.
• Pipeline: BLINCYTO® (acute lymphoblastic leukemia) and EVENITY® (osteoporosis) are global blockbusters.

Conclusion: Act Now – Buy the Durable

The MFN pricing framework and Medicare reforms are inevitable. Investors must differentiate between companies by their exposure to price controls and their ability to capitalize on global demand.

Top buys:
- ANI Pharmaceuticals (ANIP): Rare disease resilience.
- Biote (BTMD): Scalable hormone optimization.
- AbbVie (ABBV): Pipeline diversification.
- Sanofi (SNY): Global mRNA/AI advantage.

The reforms will not destroy the sector—they’ll reward companies with innovation, diversification, and focus on unmet needs.

Act now before the sector splits further.

—
This article reflects analysis as of May 20, 2025. Past performance is not indicative of future results. Consult a financial advisor before making investment decisions.